This study is being sponsored by Savara Inc. (a clinical-stage biopharmaceutical company focused on rare respiratory diseases) and being conducted by Engage Health, Inc., (a health research company). The objective of the survey is to gain a better understanding of US clinicians’ experience with EAPs and clinical management of rare pulmonary diseases. Healthcare providers are encouraged to participate in this brief, 15-minute survey and will receive a $100 honorarium for their participation.

Spaces are limited, so physicians are encouraged to join quickly and click here to participate.